Allergan (NYSE:AGN) went on the offensive again today in its battle against a hostile takeover bid by Valeant Pharmaceuticals and its hedge fund partner, Pershing Square Capital Management, demanding more transparency from Valeant about its business and prospects for growth – even as Valeant today filed a pre-merger notification with the U.S. Federal Trade Commission.
Help employers find you! Check out all the jobs and post your resume.
